John Overdeck’s Sage Therapeutics SAGE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-268,007
| Closed | -$2.44M | – | 3886 |
|
|
2025
Q2 | $2.44M | Sell |
268,007
-90,378
| -25% | -$665K | ﹤0.01% | 1694 |
|
|
2025
Q1 | $2.85M | Buy |
358,385
+228,635
| +176% | +$1.67M | 0.01% | 1502 |
|
|
2024
Q4 | $705K | Sell |
129,750
-32,046
| -20% | -$196K | ﹤0.01% | 2369 |
|
|
2024
Q3 | $1.17M | Sell |
161,796
-51,065
| -24% | -$468K | ﹤0.01% | 2034 |
|
|
2024
Q2 | $2.31M | Sell |
212,861
-115,986
| -35% | -$1.49M | 0.01% | 1453 |
|
|
2024
Q1 | $6.16M | Buy |
328,847
+79,875
| +32% | +$1.84M | 0.01% | 863 |
|
|
2023
Q4 | $5.4M | Buy |
+248,972
| New | +$4.93M | 0.01% | 951 |
|
|
2023
Q3 | – | Sell |
-4,832
| Closed | -$227K | – | 3180 |
|
|
2023
Q2 | $227K | Sell |
4,832
-42,251
| -90% | -$2.1M | ﹤0.01% | 2607 |
|
|
2023
Q1 | $1.98M | Buy |
47,083
+20,190
| +75% | +$868K | 0.01% | 1389 |
|
|
2022
Q4 | $1.03M | Sell |
26,893
-109,960
| -80% | -$4.2M | ﹤0.01% | 1686 |
|
|
2022
Q3 | $5.36M | Sell |
136,853
-39,172
| -22% | -$1.51M | 0.02% | 729 |
|
|
2022
Q2 | $5.69M | Buy |
176,025
+169,706
| +2,686% | +$5.69M | 0.02% | 715 |
|
|
2022
Q1 | $209K | Buy |
+6,319
| New | +$238K | ﹤0.01% | 2326 |
|
|
2021
Q2 | – | Sell |
-150,794
| Closed | -$11.3M | – | 4493 |
|
|
2021
Q1 | $11.3M | Buy |
150,794
+19,301
| +15% | +$1.58M | 0.03% | 654 |
|
|
2020
Q4 | $11.4M | Buy |
131,493
+58,449
| +80% | +$4.31M | 0.03% | 554 |
|
|
2020
Q3 | $4.46M | Sell |
73,044
-304,235
| -81% | -$15.4M | 0.02% | 848 |
|
|
2020
Q2 | $15.7M | Sell |
377,279
-101,746
| -21% | -$3.69M | 0.08% | 271 |
|
|
2020
Q1 | $13.8M | Buy |
479,025
+467,722
| +4,138% | +$27.1M | 0.11% | 185 |
|
|
2019
Q4 | $816K | Buy |
+11,303
| New | +$1.39M | ﹤0.01% | 2380 |
|
|
2017
Q4 | – | Sell |
-90,596
| Closed | -$5.64M | – | 3413 |
|
|
2017
Q3 | $5.64M | Buy |
+90,596
| New | +$7.12M | 0.02% | 751 |
|
|
2015
Q3 | – | Sell |
-38,186
| Closed | -$2.79M | – | 2659 |
|
|
2015
Q2 | $2.79M | Buy |
+38,186
| New | +$2.45M | 0.01% | 1020 |
|
Other funds holding SAGE
IA
HNB
John Overdeck's SAGE Position: Q3 2025 in Review
John Overdeck sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 268,007 shares — an estimated $2.44M sold.
John Overdeck first reported a position in SAGE in Q2 2015 and held it in 21 quarters. The position peaked at $15.7M in Q2 2020. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.
- John Overdeck reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
- John Overdeck sold 268,007 Sage Therapeutics shares in Q3 2025, an estimated $2.44M.
- John Overdeck first reported a position in Sage Therapeutics in Q2 2015 and held it in 21 quarters.
- John Overdeck's Sage Therapeutics position peaked at $15.7M in Q2 2020.
- 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.
Based on Two Sigma Investments's 13F filing for Q3 2025, filed 14 Nov 2025.